Luis Alfredo Carvalho

Dr. Luis Alfredo Carvalho


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2018
Verified
Conference Paper
Open access
PDF file
RSRodrigo Tavares de Souza
Rodrigo Tavares de Souza
RRRafael Castaneda Ribeiro
Rafael Castaneda Ribeiro
CFClaudia Ferlin
Claudia Ferlin
RGRonaldo Ribeiro Goldschmidt
Ronaldo Ribeiro Goldschmidt
LCLuis Alfredo Carvalho
Luis Alfredo Carvalho
JSJorge de Abreu Soares
Jorge de Abreu Soares
A tarefa de imputação de dados é um importante desafio enfrentado pelos cientistas de dados. Nesse contexto, torna-se imperativo dispor-se de técnicas de imputação que melhorem a qualidade do dado preenchido. Valer-se tanto de técnicas de aprendizado de máquina quanto de variações do processo clássico de imputação pode tornar possível a melhora da qualidade dos dados imputados. Assim, este artigo tem por propósito avaliar o impacto da utilização do algoritmo dos k-vizinhos mais próximos frente ao uso da média no processo de imputação global bem como explorar o uso da técnica de imputação hot-deck com o algoritmo de agrupamento k-Means e a imputação com k-NN. Os resultados revelam interessante redução da margem de erro obtida na simulação em três bases de dados com diferentes características.

11 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SMSergio Assuncao Monteiro
Sergio Assuncao Monteiro
LCLuis Alfredo Carvalho
Luis Alfredo Carvalho
MWMariana Caldas Waghabi
Mariana Caldas Waghabi
FSFabrício Alves Barbosa da Silva
Fabrício Alves Barbosa da Silva
Triple-negative breast cancer (TNBC) lacks effective molecular targets, leading to poor prognosis. Previous computational methods to identify targets have suffered from low druggability, high complexity, and lack of robust validation. We propose a hybrid methodology combining Boolean network modeling with semidefinite programming (SDP) to analyze a TNBC cell line network. The resulting therapeutic pair underwent a multi-level validation framework, including Boolean simulations, statistical uncertainty quantification (bootstrap), sensitivity analysis, and independent verification by AlphaGenome v2, a deep learning model from Google DeepMind. Our analysis identified TK1 and VIM as a robust therapeutic pair. Dual inhibition achieved 99.03% similarity to the apoptotic state with a 95% confidence interval of [98.79%, 99.26%], and was statistically superior to alternative pairs (p < 0.001). The selection remained optimal across all tested model parameters, demonstrating high robustness. Importantly, the pair has full druggability because both targets have available specific inhibitors. AlphaGenome v2 validation in normal mammary tissue revealed that TK1 exhibits moderate expression while VIM shows low baseline expression. This differential pattern, combined with strong VIM upregulation in the mesenchymal-like TNBC phenotype, supports the synergistic mechanism of the dual-target strategy. Our methodology identified TK1-VIM as a high-confidence and druggable therapeutic pair for TNBC with strong biological plausibility. This work provides a clinically actionable strategy and establishes a new benchmark for computational rigor in drug target identification.

Verified
Journal Article
Open access
PDF file
SMSergio Assuncao Monteiro
Sergio Assuncao Monteiro
LCLuis Alfredo Carvalho
Luis Alfredo Carvalho
MWMariana Caldas Waghabi
Mariana Caldas Waghabi
FSFabrício Alves Barbosa da Silva
Fabrício Alves Barbosa da Silva
Triple-negative breast cancer (TNBC) lacks effective molecular targets, leading to poor prognosis. Previous computational methods to identify targets have suffered from low druggability, high complexity, and lack of robust validation. We propose a hybrid methodology combining Boolean network modeling with semidefinite programming (SDP) to analyze a TNBC cell line network. The resulting therapeutic pair underwent a multi-level validation framework, including Boolean simulations, statistical uncertainty quantification (bootstrap), sensitivity analysis, and orthogonal computational support from AlphaGenome, a deep learning model from Google DeepMind. Our analysis identified TK1 and VIM as a computationally robust therapeutic pair. Dual inhibition achieved 99.03% similarity to the apoptotic state with a 95% confidence interval of [98.79%, 99.26%], and was statistically superior to alternative pairs (p<0.001). The selection remained optimal across all tested model parameters, demonstrating high robustness. Importantly, the pair has full druggability because both targets have available specific inhibitors. Orthogonal computational evidence from AlphaGenome, stratified by mammary compartment, indicated that both targets exhibit moderate baseline expression in normal mammary epithelium (TK1 = 0.159, VIM = 0.143 in normalized RNA-seq units; n = 13 tracks per gene), with VIM showing a 2.2-fold higher expression in mammary stroma than in epithelium—a gradient consistent with its established role as a mesenchymal marker. Promoter-variant proxy analysis indicated near-zero transcriptomic perturbation upon simulated inhibition of either target in normal mammary epithelium (mean |log2FC|<0.001), supporting a favorable therapeutic window. Our methodology identified TK1–VIM as a computationally robust, druggable therapeutic candidate pair with biologically plausible mechanism of action. Gene-variability analysis identified TK1 and VIM as the highest-scoring candidates, with SDP optimization providing complementary, independent confirmation of this selection. This work provides a computationally grounded candidate strategy and a rigorous methodological benchmark for computational drug target identification; experimental validation remains an essential next step before clinical translation.

6 November 2025 in bioRxiv
Verified
Preprint
Open access
SMSergio Assuncao Monteiro
Sergio Assuncao Monteiro
LCLuis Alfredo Carvalho
Luis Alfredo Carvalho
FSFabrício Alves Barbosa da Silva
Fabrício Alves Barbosa da Silva
Triple-negative breast cancer (TNBC) represents a significant clinical challenge due to the absence of well-established molecular targets and resistance to conventional therapies. Identifying synergistic combinations of therapeutic targets requires computational approaches that integrate topological network analysis, experimental validation, and clinical applicability. This work proposes a hybrid methodology that combines Semidefinite Programming (SDP) for identification of critical nodes in gene regulatory networks, Boolean simulation for quantification of perturbation efficacy, and systematic literature validation with focus on druggability and synergy. We constructed a core regulatory network of 13 genes representing key nodes in STAT3, PI3K/AKT, and p53 signaling pathways, which are frequently deregulated in TNBC. We applied three complementary SDP formulations (Max-Cut, Influence Maximization, and Spectral Clustering) to identify candidate targets, followed by stochastic Boolean simulation for calculation of the Therapeutic Index (TI). We integrated a practical applicability scoring system that considers druggability, clinical evidence, specificity, and TNBC validation. Our analysis identified the combination STAT3 + BCL2 as the most promising therapeutic pair, with an applicability score of 0.905 and average druggability of 0.85. This finding is strongly supported by extensive experimental evidence demonstrating that STAT3 directly regulates BCL2 transcription in breast cancer cells. We demonstrate a clear methodological evolution from previous approaches: from 5 genes (Tilli et al., 2016, druggability 0.32) to 3 genes ([9], druggability 0.40) and finally to 2 genes (our work, druggability 0.85), representing a 166% increase in druggability and 60% reduction in complexity. The proposed methodology offers a systematic and reproducible framework for prioritization of therapeutic targets with focus on clinical applicability, contributing to rational development of combination therapies in TNBC.